|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prevalence of overweightedness in patients with gastro-esophageal reflux显示文摘AIM: To evaluate whether the prevalence of overweight and obese conditions is increased in gastro-esophageal reflux disease (GERD) patients (with 24-h pathological pH recordings) in comparison to general population. METHODS: A total of 196 consecutive patients (103 females, age range 18-83 years) with symptoms of gastro-esophageal reflux (GER) and 24-h pathological esophageal pH-metry. Body mass index (BMI) of the patients was calculated and its distribution (%) was compared with that of the Italian general population as assessed by National Bureau of Census (ISTAT). To evaluate the association of GERD with weight categories, the binomial test was employed. P < 0.05 was considered statistically significant. RESULTS: In males, overweightedness (BMI 25-25.9) was present in 43% of GERD patients vs 41.8% of Italian population (IP) (ns), obesity (BMI ≥ 30) in 10.9% vs 9.1% (ns). In females overweight was present in 34.9% of GERD patients vs 25.7% of IP (P < 0.01), obesity in 13.6% of GERD patients vs 9.1% of IP (P < 0.01). No statistically significant differences were noted in different age classes. CONCLUSION: In comparison to the Italian general population, the prevalence of overweightedness and obesity is increased in female but not in male patients with ascertained gastro-esophageal reflux disease. | Luca Piretta Federico Alghisi Fiorella Anzini Enrico Corazziari | 2007 | World Journal of Gastroenterology2007，13，34： | 7 |
| 2 | Neoadjuvant radiotherapy dose escalation for locally advanced rectal cancers in the new era of radiotherapy:A review of literature显示文摘BACKGROUND The standard treatment of locally advanced rectal cancers(LARC)consists on neoadjuvant chemoradiotherapy followed by total mesorectal excision.Different data in literature showed a benefit on tumor downstaging and pathological complete response(pCR)rate using radiotherapy dose escalation,however there is shortage of studies regarding dose escalation using the innovative techniques for LARC(T3-4 or N1-2).AIM To analyze the role of neoadjuvant radiotherapy dose escalation for LARC using innovative radiotherapy techniques.METHODS In December 2020,we conducted a comprehensive literature search of the following electronic databases:PubMed,Web of Science,Scopus and Cochrane library.The limit period of research included articles published from January 2009 to December 2020.Screening by title and abstract was carried out to identify only studies using radiation doses equivalent dose 2 Gy fraction(EQD2)≥54 Gy and Volumetric Modulated Arc Therapy(VMAT),intensity-modulated radiotherapy or image-guided radiotherapy(IGRT)techniques.The authors’searches generated a total of 2287 results and,according to PRISMA Group(2009)screening process,21 publications fulfil selection criteria and were included for the review.RESULTS The main radiotherapy technique used consisted in VMAT and IGRT modality.The mainly dose prescription was 55 Gy to high risk volume and 45 Gy as prophylactic volume in 25 fractions given with simultaneous integrated boosts technique(42.85%).The mean pCR was 28.2%with no correlation between dose prescribed and response rates(P value≥0.5).The R0 margins and sphincter preservation rates were 98.88%and 76.03%,respectively.After a mean follow-up of 35 months local control was 92.29%.G3 or higher toxicity was 11.06%with no correlation between dose prescription and toxicities.Patients receiving EQD2 dose>58.9 Gy and BED>70.7 Gy had higher surgical complications rates compared to other group(P value=0.047).CONCLUSION Dose escalation neoadjuvant radiotherapy using innovative techniques is safe for LARC achieving higher rates of pCR.EQD2 doses>58.9 Gy is associated with higher rate of surgical complications. | Durim Delishaj Ilaria Costanza Fumagalli Stefano Ursino Agostino Cristaudo Francesco Colangelo Antonio Stefanelli Alessandro Alghisi Giuseppe De Nobili Romerai D’Amico Alessandra Cocchi Antonio Ardizzoia Carlo Pietro | 2021 | World Journal of Clinical Cases2021，9，30： | 2 |
| 3 | RNA interference against urokinase in hepatocellular carcinoma xenografts in nude mice显示文摘 | SALVI A ARICI B ALGHISI A | 2007 | Tumour Biol2007，28，： | 1 |
| 4 | Vascular integrins in tumor angiogenesis:Mediators and therapeutic targets显示文摘 | Alghisi GC Rüegg C | 2006 | Endothelium2006，13，2： | 1 |
| 5 | Vascular integrins in tumor angiogenesis:mediators and therapeutic targets显示文摘 | Alghisi GC Raegg C | | 0，，： | 1 |
| 6 | Synthesis and in vitro evalu- ation of a novel radioligand for ctv133 integrin receptor imaging: FPPA-c ( RGDfK ) 显示文摘 | Monaco A Zoete V Alghisi GC | 2013 | Bioorg Med Chem Lett2013，23，22： | 1 |
| 7 | Pectin-degrading enyme and plant-parasite interactions 显示文摘 | Alghisi P Favaron F | 1995 | European Journal of Plant Pathology1995，101，： | 1 |
| 8 | The etiology of acute recurrent pancreatitis in children:a challenge for pediatricians显示文摘 | Lucidi V Alghisi F Dall L | | 0，，4： | 1 |
| 9 | DNA topoisomerase Ⅱ mutation and resistance to anti-tumor drugs显示文摘 | Vassetzky TS Alghisi GC Gasser SM | 1995 | Bioessays1995，17，9： | 1 |
| 10 | The Integrin Antagonist Cilengitide Activates aVβ3, Disrupts VE-Cadherin Localization at Cell Junctions and Enhances Perme-ability in Endothelial Cells显示文摘 | Gian Carlo Alghisi | 2009 | Plos One2009，4，2： | 1 |
| 11 | Purification and molecular characterization of a soybean polygalacturonase-inhibiting protein显示文摘 | FAVARON F DOVIDIO R POREDDU E ALGHISI P | 1994 | Planta1994，195，： | 1 |
| 12 | Purification and molecular characterization of a soybean polygalacturonase-inhibiting protein显示文摘 | F. Favaron R. D’Ovidio E. Porceddu P. Alghisi | 1994 | Planta1994，，1： | 1 |
| 13 | Pilot study on the use of acoustic radiation force impulse imaging in the staging of cystic fibrosis associated liver disease 显示文摘 | Manco M Zupone CL Alghisi F | 2012 | J Cyst Fibros2012，11，5： | 1 |
| 14 | RNA interference against urokinase in hepatocellular carcinoma xenografts in nude mice显示文摘 | Salvi A Arici B Alghisi A | 2007 | Tumour Biol2007，28，1： | 1 |
| 15 | Pectin-degrading enyme and plant-parasite interactions显示文摘 | Alghisi P Favaron F | 1995 | European Journal of Plant Pathology1995，101，： | 1 |
| 16 | RNA interference against urokinase in hepatocellular carcinoma xenografts in nude mice 显示文摘 | Salvi A Arici B Alghisi A | 2007 | Tumour Biol2007，28，1： | 1 |
| 17 | Vascular intergrins in tumor angiogenesis:Mediators and therapeutic targets显示文摘 | Alghisi GC Ruegg C | 2006 | Endothelium2006，13，9： | 1 |
| 18 | Pectin-degrading enzymes and plant parasite interactions显示文摘 | Alghisi P Favaron F | 1995 | European Journal of Plant Pathology1995，101，4： | 1 |
| 19 | Purification and molecular characterization of a soybean polygalacturonase-inhibiting protein显示文摘 | FAVARON F D'OVIDIO R POREDDU E ALGHISI P | 1994 | Planta1994，195，： | 1 |
| 20 | The inte- grin antagonist cilengitide activates oLVI33, sisrupts VE-Cadherin lo- calization at cell junctions and enhances permeability in endothelial cells显示文摘 | Gian Carlo Alghisi Lionel Ponsonnet and Curzio R0 egg | 2009 | PLoS ONE2009，4，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员